By Katherine Hamilton
Aytu BioPharma reported quarterly revenue below Wall Street's expectations, and a wider loss than anticipated. The stock fell 14% to $2.16 after the bell on Tuesday.
Cohu plans to offer $200 million in convertible senior notes due in 2031. Shares declined 10% to $20.59 in after-hours trading.
Cyclerion Therapeutics entered a licensing agreement with the Massachusetts Institute of Technology securing intellectual property for its strategic relaunch. The stock soared 39% to $4.21.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
September 23, 2025 19:17 ET (23:17 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.